Comparative Pharmacology
Head-to-head clinical analysis: DOXY 100 versus TETRACHEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOXY 100 versus TETRACHEL.
DOXY 100 vs TETRACHEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Doxycycline inhibits bacterial protein synthesis by reversibly binding to the 30S ribosomal subunit, preventing the addition of amino acids to the growing peptide chain. It also exhibits anti-inflammatory effects by inhibiting matrix metalloproteinases and reducing cytokine production.
Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
100 mg orally or intravenously every 12 hours on day 1, then 100 mg daily.
500 mg orally once daily for 28 days; for severe infections, 500 mg twice daily for 14 days.
None Documented
None Documented
Terminal elimination half-life is 18-22 hours in adults; prolonged to 20-30 hours in renal impairment.
6-11 hours (prolonged in renal impairment; up to 57 hours in anuria).
Renal (approximately 40% as unchanged drug) and fecal/biliary (approximately 50-60% as inactive metabolites and unchanged drug).
Renal 60% (glomerular filtration), fecal 40% (biliary excretion of active drug and metabolites).
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic